Allied OMS: Surgeon-Owned MSO That Flipped PE

Most dental consolidators are investor-controlled platforms that buy practices and hand surgeons a minority of the upside. Allied OMS was built to invert that arrangement. Launched in 2020 — in the pandemic's first year — by an independent sponsor and two founding oral-surgery practices, the Southlake, Texas platform brands itself as "doctor-owned, doctor-led, and doctor-governed," with a board that is three-quarters network surgeons. For an investor mapping where oral and maxillofacial surgery (OMS) consolidation goes next, Allied OMS is the clearest test of whether a surgeon-majority governance model can scale as fast as the capital-led roll-ups it competes against.

Overview

Allied OMS is a management services organization (MSO) headquartered in Southlake, Texas, that exclusively supports oral and maxillofacial surgery practices. The company describes itself as a "doctor-owned, doctor-led, and doctor-governed" MSO that "combines the best of private practice with the best of private equity."¹ Trade publications, including Becker's Dental + DSO Review and DrBicuspid, frequently categorize it as a dental service organization (DSO); in this OMS context the MSO/DSO distinction is largely terminological — both describe a platform that provides centralized non-clinical support to affiliated practices while surgeons retain clinical control.²

The platform's organizing idea is what the company trademarks as "Doctor Equity." In a conventional private-equity-backed roll-up, a financial sponsor controls the board and captures most of the equity value; Allied OMS instead positions the network surgeons as collective owners of the parent company and gives them majority governance. The company reports that 75% of its board directors are doctor-owners and that 100% of its management committees are chaired by network surgeons.³ That structure — not its specialty focus alone — is what differentiates Allied OMS from the broader field of OMS consolidators.

Oral and maxillofacial surgery sits at the intersection of dentistry and medicine, spanning routine extractions and dental implants at one end and orthognathic (jaw) surgery, facial trauma, and pathology at the other. These are high-acuity, capital-intensive practices carrying anesthesia, surgical suites, and advanced imaging — a case mix that has made OMS one of the most actively consolidated dental specialties, and the reason a surgeon-aligned governance pitch resonates with practice owners weighing a partner.

Company Snapshot

• Founded: 2020, by independent sponsor DuneGlass Capital together with founding practices Fort Worth Oral Surgery (Texas) and Evergreen Oral & Maxillofacial Surgery (Colorado).³
• Headquarters: Southlake, Texas.¹
• Model: Single-specialty MSO/DSO for oral and maxillofacial surgeons — centralized non-clinical support (finance, HR, revenue-cycle, marketing, recruiting, operations, data) to surgeon-owned partner practices, paired with equity participation in the parent ("Doctor Equity").¹
• Footprint: Company-reported 50+ locations across roughly a dozen states as of late 2025 (counts vary by source and date — see Footprint Analysis).⁴
• Governance: Doctor-majority board (reported 75% doctor-owners); 100% of management committees chaired by network surgeons.³
• Ownership: Collectively owned by network surgeons alongside founding sponsor DuneGlass Capital; received a significant minority growth investment from 65 Equity Partners (with Everberg Capital co-investing) in June 2025 — its first institutional equity capital.⁵
• Leadership: Dan Hosler (co-founder and CEO; reportedly also a Managing Partner of DuneGlass Capital), Ryan Graham (DuneGlass co-founder and Allied OMS board member, reported to lead operations), Dr. Jonathon Jundt (founding surgeon and board director, reported clinical lead), Brian Hamilton (reported Chief Development Officer), Bill Murray (CFO, appointed September 2025).¹
• Revenue: Not publicly disclosed. The company has reported doubling revenue and EBITDA over an early growth period, but no audited or company-confirmed top-line figure is available.³

Business Model

Allied OMS operates the standard MSO playbook with a deliberately non-standard cap table. It does not practice surgery; it manages the non-clinical side of partner practices — finance and accounting, human resources, revenue-cycle and insurance functions, marketing, recruiting, operations, and data analytics — while surgeons retain clinical autonomy and continue to own the professional entities that deliver care.¹ That separation is what keeps the model compliant with corporate-practice-of-dentistry and -medicine doctrines that, in many states, bar non-clinicians from directing a clinical practice.

What sets the model apart is the equity arrangement the company brands as "Doctor Equity." Rather than treating affiliated surgeons purely as sellers, Allied OMS structures them as ongoing shareholders in the parent organization, so they share in the platform's enterprise value rather than only realizing a one-time sale price.¹ The company frames this as turning "private equity into doctor equity" — reallocating the governance control and economic upside that financial sponsors typically capture toward the clinicians themselves. The precise split of equity among network surgeons, founding sponsor DuneGlass Capital, and the institutional investors that entered in 2025 is not disclosed, so the exact distribution of economic rights is undisclosed and worth noting for any investor sizing the platform.

This positioning is also a recruiting tool. In a competitive market where OMS practices field repeated approaches from capital-led consolidators, Allied OMS markets surgeon governance and equity alignment — its trademarked "Power Through Partnership" system — as the reason a practice should choose it over a larger but more investor-controlled buyer. The comparison most often drawn is to fellow specialty MSOs like USOSM, which similarly emphasizes surgeon equity, and to multi-specialty platforms such as Specialized Dental Partners and Specialty1 Partners.

Footprint Analysis

Allied OMS's footprint is best read as company-reported and rounded, because the counts have moved quickly and the company tends to cite "locations" and "surgeons" rather than a fixed practice count. As of September 2023, the company reported 65 doctors across 46 locations in 12 states — California, Colorado, Illinois, Louisiana, Maryland, Michigan, Mississippi, New York, Oregon, Tennessee, Texas, and Virginia.³ By late 2025 it was reporting 50+ locations, with continued additions in Arizona (2024), and Indiana and New Jersey (2025).⁴

A note of caution on interpreting these figures: offices, locations, and practices are not interchangeable, and a single partner practice may operate several offices. Allied OMS's reported counts should be treated as approximate and directional rather than precise. The platform's center of gravity is Texas, where management has stated an explicit strategy to establish a presence in every major metropolitan market — Dallas, Fort Worth, San Antonio, Houston, and (as of 2025) the Greater Austin area.⁴ That Texas density is both a strength — referral and operational economies of scale in its home market — and a reminder that the national network, while spread across roughly a dozen states, is still concentrated.

Growth History

The platform's arc is a fast one. Founded in 2020 by DuneGlass Capital and its two anchor practices, Allied OMS reported adding 30 independent practices in its first three years, reaching 65 surgeons across 12 states by September 2023 — a pace the company characterized as "tripling" its platform.³ Brian Hamilton, the platform's development lead and recognized regionally as a 2023 "Dealmaker of the Year," has publicly described leading well over a dozen partnership transactions, underscoring an acquisition-led growth engine running alongside organic, de novo expansion.⁴

The capital story matured in parallel with the practice count. In May 2024, Allied OMS closed a $116 million credit facility — its first round of outside financing — arranged by KeyBanc Capital Markets with a syndicate including BankUnited, Umpqua Bank, and First-Citizens.⁶ In June 2025 it raised its first institutional equity: a significant minority growth investment from 65 Equity Partners, with Everberg Capital co-investing.⁵ Shortly after, in August 2025, Comvest Credit Partners served as administrative agent on a $245 million senior secured facility that refinanced existing debt and funded further growth.⁴

Competitive Landscape

Oral and maxillofacial surgery is one of the more contested corners of dental consolidation, and Allied OMS competes for the same independent practices as several well-capitalized platforms. The most direct comparison is USOSM — the first and largest oral-surgery-only MSO, which also leads with a surgeon-equity message but is controlled by a private-equity sponsor. Multi-specialty consolidators such as Specialized Dental Partners and Specialty1 Partners also pursue OMS practices as part of broader surgical-specialty portfolios, and large generalist DSOs occasionally fold OMS into wider networks.

Against that field, Allied OMS's differentiator is governance rather than scale: it is smaller than USOSM but markets a doctor-majority board and broader equity participation as a structurally distinct alternative. Its watch-item, from a competitive standpoint, is that the surgeon-governance pitch is increasingly echoed by rivals, so execution — deal cadence, integration quality, and the durability of the doctor-majority model as outside institutional capital scales — will determine whether the positioning remains a genuine moat.

Market Position

For an OMS practice owner choosing a partner, Allied OMS occupies a clear niche: the surgeon-control option. Its pitch is that doctors keep majority governance and meaningful equity while still gaining the centralized infrastructure — revenue-cycle management, recruiting, data, and purchasing scale — that a standalone practice cannot easily build. For the broader market, Allied OMS is a useful data point on whether a doctor-majority governance structure can attract institutional capital without surrendering the very control that defines its brand.

The June 2025 entry of 65 Equity Partners — a firm backed by Singapore's Temasek and focused on long-term, family- and founder-aligned investing — is the most consequential signal of that position. It validates the platform's growth story while raising the central question for the years ahead: how the "doctor-majority" promise is preserved as larger pools of outside equity and debt enter the structure. That is the tension worth watching as the platform scales.

TMR Take: For operators: Allied OMS is the surgeon-control option in OMS consolidation — doctor-majority board, equity participation, and centralized non-clinical support, with notable Texas density. If keeping governance and a real equity stake matters more to you than affiliating with the largest possible network, it merits a close look alongside USOSM. For vendors: This is a centralized, data-forward MSO that standardizes finance, revenue-cycle, marketing, and recruiting across the network — meaning purchasing and software decisions increasingly run through Southlake rather than individual practices. The OMS-specific stack (anesthesia documentation, surgical and 3D imaging, medical-and-dental billing) is the relevant entry point, and how standardized it already is across partners is the key qualifying question. For investors: Allied OMS is a surgeon-owned, doctor-governed OMS MSO founded in 2020 by DuneGlass Capital and two anchor practices, reporting 50+ locations across roughly a dozen states. State the ownership precisely: it remained doctor-and-sponsor owned with no institutional equity until June 2025, when 65 Equity Partners made a significant minority growth investment (Everberg Capital co-investing) — not a control buyout — alongside a Comvest-administered $245M senior secured facility in August 2025. Watch items: an undisclosed top line (no company-confirmed revenue to model from), the exact post-2025 equity split among surgeons, DuneGlass, and the new investors, and whether the doctor-majority governance model holds as institutional capital scales.

Sources

1. Allied OMS — company website and corporate press releases (headquarters, model, leadership, governance, and "Doctor Equity" structure).

2. Industry categorization — Becker's Dental + DSO Review and DrBicuspid coverage of Allied OMS.

3. Founding and governance — Allied OMS / DuneGlass Capital platform-growth press releases (formation, founding practices, doctor-majority board, and early footprint).

4. Footprint, growth, and transactions — Allied OMS partnership announcements and Comvest Credit Partners financing release.

5. Institutional investment — Allied OMS and 65 Equity Partners growth-investment announcements (minority investment; Everberg Capital co-investor).

6. Debt financing — Allied OMS $116 million credit facility press release (KeyBanc-led syndicate).